Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1361-1380 of 2,251 trials

Autoimmune Hemolytic Anemia: Anticoagulation Study

We are testing whether prolonged anticoagulation therapy can help prevent blood clots in patients with autoimmune hemolytic anemia. This study will also look at how well patients tolerate the treatment and the timing of any clotting events.

Autoimmune Hemolytic Anemia>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInternal Medicine

Multiple Sclerosis: Personalized Ocrelizumab Treatment

We are studying whether a tailored dosing of ocrelizumab is as effective as the standard treatment in managing relapsing remitting multiple sclerosis. This trial aims to improve treatment personalization for better disease control.

Multiple Sclerosis>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurology

Lanreotide and Metformin for Advanced Carcinoids

We are studying the safety of a new treatment combining Lanreotide and Metformin for patients with advanced gastrointestinal or lung carcinoids. This trial aims to understand how well this combination works and its effects on symptoms.

Advanced Progressive Gastro-Intestinal or Lung Carcinoids>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Axial Spondyloarthritis: NSAIDs vs. Biosimilar TNF Blockers

We are comparing the effectiveness of high-dose NSAIDs and a biosimilar TNF blocker for patients with axial spondyloarthritis who haven't responded to NSAIDs. The study will also look at side effects and inflammation levels.

Axial Spondyloarthritis3-6 monthsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Fungal Nail Infection: MOB015B Solution for Kids

We are studying a new topical solution for treating mild to moderate fungal infections of the nail in children aged 6 to 17. The goal is to see how well it works and how safe it is.

Distal Subungual Onychomycosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyInfectious DiseasesPediatrics

Cariprazine for Adolescents with Schizophrenia

We are studying the safety and tolerability of cariprazine in adolescents aged 13 to under 18 with schizophrenia. This trial aims to see how well the medication works and its impact on health-related outcomes.

Schizophrenia>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsPsychiatry

Vertebral Metastases: Zoledronic Acid or Denosumab with Radiation

We are studying whether adding zoledronic acid or denosumab to stereotactic radiotherapy improves treatment outcomes for patients with vertebral metastases. This trial will also look at cost-effectiveness and various health impacts.

Metastatic Bone Pain>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

Hormonal Treatment for Adolescents with Gender Dysphoria

We are studying the effects of starting hormonal treatment at age 14 on the well-being of adolescents with gender dysphoria. This research aims to assess both the effectiveness and safety of the treatment as they transition into adulthood.

Gender Dysphoria>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyPsychiatry

Peripheral T-Cell Lymphoma: Lacutamab with GemOx

We are studying a new treatment combining Lacutamab with GemOx for patients with relapsed or refractory peripheral T-cell lymphoma. The trial aims to evaluate its effectiveness and safety compared to GemOx alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Gastric Cancer: [18F]AlF-FAPI-74 PET/CT Study

We are testing a new imaging method to improve the staging of advanced gastric cancer. This study aims to see if it can reduce the need for invasive procedures while providing accurate diagnostic information.

Advanced Gastric CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal MedicineOncology

Scabies Treatment: Testing Permethrin Cream

We are studying the effectiveness of a new higher-concentration permethrin cream for treating scabies in adults and children. The trial aims to see if this treatment works better than the standard cream and how safe it is.

Scabies>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesDermatologyInfectious Diseases

RSV Vaccination in Stem Cell Transplant Recipients

We are studying two RSV vaccines to see how well they work in patients who have received stem cell transplants. The goal is to understand their immune response and effectiveness compared to healthy individuals.

Allogeneic Hematopoietic Stem Cell Transplantation≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesInternal Medicine

Alternative Antibiotics for Resistant UTIs

We are testing new oral antibiotics for patients with febrile urinary tract infections caused by resistant bacteria. The goal is to see if these alternatives are as safe as current treatments.

Urinary Tract Infection (UTI) from Resistant Bacteria>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInfectious DiseasesUrology

Crohn's and Colitis: Stopping Anti-TNF Treatment

We are studying if specific markers can help identify patients who can safely stop their anti-TNF treatment while in remission. This may help tailor treatment plans for better health outcomes.

Ulcerative ColitisCrohn's Disease>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Urethral Stenosis: Innovative Fat Injection Treatment

We are studying the safety and potential benefits of injecting fat-derived cells for men with recurrent urethral stenosis after surgery. This trial aims to see if this treatment can improve symptoms and reduce the need for further procedures.

Urethral Stenosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesUrology

Relapsed or Refractory PCNSL: Emavusertib Study

We are studying the safety and effectiveness of a new oral medication, emavusertib, for patients with relapsed or refractory primary central nervous system lymphoma. This trial also explores its use alongside another treatment, ibrutinib.

Hematological MalignancyPrimary Central Nervous System Lymphoma (PCNSL)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Early-Stage Colon Cancer: NICHE Trial for Immunotherapy

We are studying a new immunotherapy treatment for patients with early-stage colon cancer to see if it can reduce tumors before surgery. The trial also aims to identify biomarkers that may help tailor treatments and improve patient outcomes.

Colon or Rectosigmoid Adenocarcinoma≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Ventilator-Associated Pneumonia: Antimicrobial Stewardship Study

We are exploring a new method for managing antibiotics in patients with Ventilator-Associated Pneumonia in intensive care. This study aims to see if daily assessments can improve survival and reduce complications.

Ventilator Associated PneumoniaIntensive Care>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Transfusion-Dependent β-Thalassemia: CTX001 Treatment

We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.

Transfusion-Dependent Thalassemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics